BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 22.8] [Reference Citation Analysis]
Number Citing Articles
1 Kelava T, Turcic P, Markotic A, Ostojic A, Sisl D, Mrzljak A. Importance of genetic polymorphisms in liver transplantation outcomes. World J Gastroenterol 2020; 26(12): 1273-1285 [PMID: 32256016 DOI: 10.3748/wjg.v26.i12.1273] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Herzer K, Sterneck M, Welker MW, Nadalin S, Kirchner G, Braun F, Malessa C, Herber A, Pratschke J, Weiss KH, Jaeckel E, Tacke F. Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany. J Clin Med 2020;9:E3570. [PMID: 33167567 DOI: 10.3390/jcm9113570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pourrat X, Berthy E, Dupuis A, Barbier L, Buchler M, Guillon LG, Monmousseau F, Ruspini E, Salamé E, Houdard SB, Giraudeau B. Implementing a personalized pharmaceutical plan in kidney or liver transplant patients: study protocol for a stepped-wedge cluster randomized trial (GRePH). Trials 2021;22:782. [PMID: 34749777 DOI: 10.1186/s13063-021-05749-w] [Reference Citation Analysis]
4 Kaundal U, Ramachandran R, Arora A, Kenwar DB, Sharma RR, Nada R, Minz M, Jha V, Rakha A. Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant Patients. Stem Cells Int 2022;2022:2154544. [PMID: 35211176 DOI: 10.1155/2022/2154544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wiebe C, Kosmoliaptsis V, Pochinco D, Gibson IW, Ho J, Birk PE, Goldberg A, Karpinski M, Shaw J, Rush DN, Nickerson PW. HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. Am J Transplant 2019;19:1708-19. [PMID: 30414349 DOI: 10.1111/ajt.15177] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 14.0] [Reference Citation Analysis]
6 Beck DK, Tielen M, Rechards M, Timman R, Boonstra C, Versteegh J, van de Wetering J, Zietse R, van Gelder T, Weimar W, van Saase J, van Busschbach J, Massey EK. Comparison of a home-based (multi) systemic intervention to promoting Medication AdheRence and Self-management among kidney transplant recipients with care-as-usual: the MARS randomized controlled trial protocol. BMC Nephrol 2020;21:374. [PMID: 32859157 DOI: 10.1186/s12882-020-02008-z] [Reference Citation Analysis]
7 Wiebe C, Nickerson PW. Role of HLA molecular mismatch in clinical practice. Hum Immunol 2021:S0198-8859(21)00258-5. [PMID: 34887099 DOI: 10.1016/j.humimm.2021.11.005] [Reference Citation Analysis]
8 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
9 van Gelder T, Meziyerh S, Swen JJ, de Vries APJ, Moes DJAR. The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients. Front Pharmacol 2020;11:1142. [PMID: 32848756 DOI: 10.3389/fphar.2020.01142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Hoppmann N, Massoud O. Medical care of liver transplant patients. Expert Rev Gastroenterol Hepatol 2020;14:901-18. [PMID: 32684007 DOI: 10.1080/17474124.2020.1797483] [Reference Citation Analysis]
11 Holderried M, Hoeper A, Holderried F, Heyne N, Nadalin S, Unger O, Ernst C, Guthoff M. Attitude and potential benefits of modern information and communication technology use and telemedicine in cross-sectoral solid organ transplant care. Sci Rep 2021;11:9037. [PMID: 33907269 DOI: 10.1038/s41598-021-88447-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Oomen L, Bootsma-robroeks C, Cornelissen E, Wall LD, Feitz W. Pearls and Pitfalls in Pediatric Kidney Transplantation After 5 Decades. Front Pediatr 2022;10:856630. [DOI: 10.3389/fped.2022.856630] [Reference Citation Analysis]
13 Millson C, Considine A, Cramp ME, Holt A, Hubscher S, Hutchinson J, Jones K, Leithead J, Masson S, Menon K, Mirza D, Neuberger J, Prasad R, Pratt A, Prentice W, Shepherd L, Simpson K, Thorburn D, Westbrook R, Tripathi D. Adult liver transplantation: UK clinical guideline - part 2: surgery and post-operation. Frontline Gastroenterol 2020;11:385-96. [PMID: 32879722 DOI: 10.1136/flgastro-2019-101216] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Wang Y, Snoep JD, Hemmelder MH, van der Bogt KEA, Bos WJW, van der Boog PJM, Dekker FW, de Vries APJ, Meuleman Y. Outcomes after kidney transplantation, let's focus on the patients' perspectives. Clin Kidney J 2021;14:1504-13. [PMID: 34084453 DOI: 10.1093/ckj/sfab008] [Reference Citation Analysis]
15 Dobbels F, Vanhoof J, Schoemans H, Duerinckx N, Verbeeck I, De Geest S. Improving medication adherence: The proof of the pudding will be in the eating. Liver Transpl 2018;24:9-11. [PMID: 29194957 DOI: 10.1002/lt.24988] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Wiltshire G, Clarke NJ, Phoenix C, Bescoby C. The role of sport-based social networks in the management of long-term health conditions: Insights from the World Transplant Games. International Review for the Sociology of Sport 2022;57:256-72. [DOI: 10.1177/1012690220979202] [Reference Citation Analysis]
17 Park GC, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Yoon YI, Cho HD, Kwon JH, Chung YK, Kang SH, Choi JU, Jung IJ, Lee SG. Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation. J Korean Med Sci 2020;35:e69. [PMID: 32193900 DOI: 10.3346/jkms.2020.35.e69] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Lerut JP, Gondolesi GE. Immunosuppression in liver and intestinal transplantation. Best Pract Res Clin Gastroenterol 2021;54-55:101767. [PMID: 34874848 DOI: 10.1016/j.bpg.2021.101767] [Reference Citation Analysis]
19 Muduma G, Aluvihare V, Clancy M, de Nigris E, Whitlock C, Landeira M, Nazir J. The Last Year Before Graft Failure Negatively Impacts Economic Outcomes and is Associated With Greater Healthcare Resource Utilization Compared With Previous Years in the United Kingdom: Results of a Retrospective Observational Study. Transplant Direct 2019;5:e443. [PMID: 31165078 DOI: 10.1097/TXD.0000000000000884] [Reference Citation Analysis]
20 Schönfeld S, Denhaerynck K, Berben L, Dobbels F, Russell CL, Crespo-Leiro MG, De Geest S; BRIGHT Study Team†. Prevalence and Correlates of Cost-Related Medication Nonadherence to Immunosuppressive Drugs After Heart Transplantation: The International Multicenter Cross-sectional Bright Study. J Cardiovasc Nurs 2020;35:519-29. [PMID: 32433348 DOI: 10.1097/JCN.0000000000000683] [Reference Citation Analysis]
21 Wiltshire G, Clarke NJ, Phoenix C, Bescoby C. Organ Transplant Recipients' Experiences of Physical Activity: Health, Self-Care, and Transliminality. Qual Health Res 2021;31:385-98. [PMID: 33124516 DOI: 10.1177/1049732320967915] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Dew MA, Posluszny DM, DiMartini AF, Myaskovsky L, Steel JL, DeVito Dabbs AJ. Posttransplant Medical Adherence: What Have We Learned and Can We Do Better? Curr Transplant Rep 2018;5:174-88. [PMID: 30416933 DOI: 10.1007/s40472-018-0195-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
23 Bunthof KLW, Al-Hassany L, Nakshbandi G, Hesselink DA, van Schaik RHN, Ten Dam MAGJ, Baas MC, Hilbrands LB, van Gelder T. A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients. Clin Transl Sci 2021. [PMID: 34905302 DOI: 10.1111/cts.13206] [Reference Citation Analysis]
24 Wiebe C, Rush DN, Nevins TE, Birk PE, Blydt-Hansen T, Gibson IW, Goldberg A, Ho J, Karpinski M, Pochinco D, Sharma A, Storsley L, Matas AJ, Nickerson PW. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. J Am Soc Nephrol 2017;28:3353-62. [PMID: 28729289 DOI: 10.1681/ASN.2017030287] [Cited by in Crossref: 115] [Cited by in F6Publishing: 48] [Article Influence: 23.0] [Reference Citation Analysis]
25 Khalid U, Newbury LJ, Simpson K, Jenkins RH, Bowen T, Bates L, Sheerin NS, Chavez R, Fraser DJ. A urinary microRNA panel that is an early predictive biomarker of delayed graft function following kidney transplantation. Sci Rep 2019;9:3584. [PMID: 30837502 DOI: 10.1038/s41598-019-38642-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
26 Shen T, Zhuang L, Sun XD, Qi XS, Wang ZH, Li RD, Chang WX, Yang JY, Yang Y, Zheng SS, Xu X. Expert consensus on management of metabolic disease in Chinese liver transplant recipients. World J Gastroenterol 2020; 26(27): 3851-3864 [PMID: 32774062 DOI: 10.3748/wjg.v26.i27.3851] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Nie H, Wang W, Zhao Y, Zhang X, Xiao Y, Zeng Q, Zhang C, Zhang L. New-Onset Diabetes After Renal Transplantation (NODAT): Is It a Risk Factor for Renal Cell Carcinoma or Renal Failure? Ann Transplant 2019;24:62-9. [PMID: 30713333 DOI: 10.12659/AOT.909099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
28 Hashim M, Alsebaey A, Ragab A, Soliman HE, Waked I. Reply to: “correspondence about “Efficacy and safety of basiliximab”. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100679] [Reference Citation Analysis]
29 Marsicano-Souza EO, Colugnati F, Geest S, Sanders-Pinheiro H. Nonadherence to immunosuppressives and treatment in kidney transplant: ADHERE BRAZIL Study. Rev Saude Publica 2021;55:33. [PMID: 34076208 DOI: 10.11606/s1518-8787.2021055002894] [Reference Citation Analysis]
30 Neuberger J. LONG-TERM care of the ADUT liver transplant recipient. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.03.012] [Reference Citation Analysis]
31 Angelico R, Sensi B, Manzia TM, Tisone G, Grassi G, Signorello A, Milana M, Lenci I, Baiocchi L. Chronic rejection after liver transplantation: Opening the Pandora’s box. World J Gastroenterol 2021; 27(45): 7771-7783 [PMID: 34963740 DOI: 10.3748/wjg.v27.i45.7771] [Reference Citation Analysis]
32 Friman S, Tisone G, Nevens F, Lehner F, Santaniello W, Bechstein WO, Zhuvarel SV, Isoniemi H, Rummo OO, Klempnauer J, Anaokar S, Hurst M, Kazeem G, Undre N, Trunečka P. Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study. Transplant Direct 2021;7:e722. [PMID: 34263020 DOI: 10.1097/TXD.0000000000001166] [Reference Citation Analysis]
33 Baghai Arassi M, Gauche L, Schmidt J, Höcker B, Rieger S, Süsal C, Tönshoff B, Fichtner A. Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk. Pediatr Nephrol 2022. [PMID: 35166920 DOI: 10.1007/s00467-022-05426-3] [Reference Citation Analysis]
34 Metz DK, Holford N, Kausman JY, Walker A, Cranswick N, Staatz CE, Barraclough KA, Ierino F. Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. Transplantation 2019;103:2012-30. [PMID: 31584924 DOI: 10.1097/TP.0000000000002762] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 7.5] [Reference Citation Analysis]
35 van der Zwan M, Hesselink DA, van den Hoogen MWF, Baan CC. Costimulation Blockade in Kidney Transplant Recipients. Drugs 2020;80:33-46. [PMID: 31749062 DOI: 10.1007/s40265-019-01226-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
36 Deen CPJ, Veen AV, Gomes-Neto AW, Geleijnse JM, Berg KJBD, Heiner-Fokkema MR, Kema IP, Bakker SJL. Urinary Excretion of N1-Methylnicotinamide and N1-Methyl-2-Pyridone-5-Carboxamide and Mortality in Kidney Transplant Recipients. Nutrients 2020;12:E2059. [PMID: 32664445 DOI: 10.3390/nu12072059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Yadav K, Vock DM, Matas AJ, Robiner WN, Nevins TE. Medication adherence is associated with an increased risk of cancer in kidney transplant recipients: a cohort study. Nephrol Dial Transplant 2019;34:364-70. [PMID: 30102328 DOI: 10.1093/ndt/gfy210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
38 Manzia TM, Angelico R, Gazia C, Lenci I, Milana M, Ademoyero OT, Pedini D, Toti L, Spada M, Tisone G, Baiocchi L. De novo malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature. World J Gastroenterol 2019; 25(35): 5356-5375 [PMID: 31558879 DOI: 10.3748/wjg.v25.i35.5356] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
39 Kaundal U, Bagai U, Rakha A. Immunomodulatory plasticity of mesenchymal stem cells: a potential key to successful solid organ transplantation. J Transl Med 2018;16:31. [PMID: 29448956 DOI: 10.1186/s12967-018-1403-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
40 Lerut J, Iesari S, Foguenne M, Lai Q. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? Transl Gastroenterol Hepatol 2017;2:80. [PMID: 29167827 DOI: 10.21037/tgh.2017.09.06] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
41 Toti L, Manzia TM, Sensi B, Blasi F, Baiocchi L, Lenci I, Angelico R, Tisone G. Towards tolerance in liver transplantation. Best Pract Res Clin Gastroenterol 2021;54-55:101770. [PMID: 34874844 DOI: 10.1016/j.bpg.2021.101770] [Reference Citation Analysis]
42 Neuberger J. Immunosuppression in gastroenterology and hepatology. Best Pract Res Clin Gastroenterol 2021;54-55:101758. [PMID: 34874842 DOI: 10.1016/j.bpg.2021.101758] [Reference Citation Analysis]
43 Udomkarnjananun S, Francke MI, De Winter BCM, Mulder MB, Baan CC, Metselaar HJ, den Hoed CM, Hesselink DA. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101756. [PMID: 34874840 DOI: 10.1016/j.bpg.2021.101756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Girerd S, Schikowski J, Girerd N, Duarte K, Busby H, Gambier N, Ladrière M, Kessler M, Frimat L, Aarnink A. Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014. BMC Nephrol 2018;19:232. [PMID: 30219043 DOI: 10.1186/s12882-018-1014-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
45 Echterdiek F, Schwenger V, Döhler B, Latus J, Kitterer D, Heemann U, Süsal C. Kidneys From Elderly Deceased Donors-Is 70 the New 60? Front Immunol 2019;10:2701. [PMID: 31827468 DOI: 10.3389/fimmu.2019.02701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
46 Nevins TE, Nickerson PW, Dew MA. Understanding Medication Nonadherence after Kidney Transplant. J Am Soc Nephrol 2017;28:2290-301. [PMID: 28630231 DOI: 10.1681/ASN.2017020216] [Cited by in Crossref: 62] [Cited by in F6Publishing: 19] [Article Influence: 12.4] [Reference Citation Analysis]
47 Kostalova B, Mala-Ladova K, Kubena AA, Horne R, Dusilova Sulkova S, Maly J. Changes in Beliefs About Post-Transplant Immunosuppressants Over Time and Its Relation to Medication Adherence and Kidney Graft Dysfunction: A Follow-Up Study. Patient Prefer Adherence 2021;15:2877-87. [PMID: 35002225 DOI: 10.2147/PPA.S344878] [Reference Citation Analysis]
48 Miao K, Zhang L. Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review. Interdiscip Sci 2021. [PMID: 34152556 DOI: 10.1007/s12539-021-00437-4] [Reference Citation Analysis]
49 Mulder MB, Borgsteede SD, Darwish Murad S, Landman CS, Metselaar HJ, Hunfeld NGM. Medication-Related Problems in Liver Transplant Recipients in the Outpatient Setting: A Dutch Cohort Study. Front Pharmacol 2021;12:637090. [PMID: 33986672 DOI: 10.3389/fphar.2021.637090] [Reference Citation Analysis]
50 van der Zwan M, Clahsen-Van Groningen MC, Roodnat JI, Bouvy AP, Slachmuylders CL, Weimar W, Baan CC, Hesselink DA, Kho MML. The Efficacy of Rabbit Anti-Thymocyte Globulin for Acute Kidney Transplant Rejection in Patients Using Calcineurin Inhibitor and Mycophenolate Mofetil-Based Immunosuppressive Therapy. Ann Transplant 2018;23:577-90. [PMID: 30115901 DOI: 10.12659/AOT.909646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Niu Q, Mendoza Rojas A, Dieterich M, Roelen DL, Clahsen-van Groningen MC, Wang L, van Gelder T, Hesselink DA, van Besouw NM, Baan CC. Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients. Front Immunol 2020;11:1972. [PMID: 32983131 DOI: 10.3389/fimmu.2020.01972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
52 Zachciał J, Uchmanowicz I, Czapla M, Krajewska M, Banasik M. The Association between Adherence to Immunosuppressive Therapies after Renal Transplantation and Psychosocial and Age-Related Declines. JCM 2022;11:2386. [DOI: 10.3390/jcm11092386] [Reference Citation Analysis]
53 Myaskovsky L, Jesse MT, Kuntz K, Leino AD, Peipert JD, Russell CL, Spivey CA, Sulejmani N, Dew MA. Report from the American Society of Transplantation Psychosocial Community of Practice Adherence Task Force: Real-world options for promoting adherence in adult recipients. Clin Transplant 2018;32:e13353. [PMID: 30022527 DOI: 10.1111/ctr.13353] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
54 Mo H, Kim SY, Min S, Han A, Ahn S, Min SK, Lee H, Ahn C, Kim Y, Ha J. Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation. Transplant Direct 2019;5:e455. [PMID: 31321291 DOI: 10.1097/TXD.0000000000000899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
55 Colmenero J, Berenguer M, Watt KD. The ILTS-SETH Consensus Conference on Extrahepatic Cancer and Liver Transplantation: Paving the Way. Transplantation 2022;106:e1-2. [PMID: 34905757 DOI: 10.1097/TP.0000000000003994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Sharma A, Cherukuri A, Mehta RB, Sood P, Hariharan S. High Calcineurin Inhibitor Intrapatient Variability Is Associated With Renal Allograft Inflammation, Chronicity, and Graft Loss. Transplant Direct 2019;5:e424. [PMID: 30882028 DOI: 10.1097/TXD.0000000000000862] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
57 Deen CPJ, van der Veen A, van Faassen M, Minović I, Gomes-Neto AW, Geleijnse JM, Borgonjen-van den Berg KJ, Kema IP, Bakker SJL. Urinary Excretion of N1-Methylnicotinamide, as a Biomarker of Niacin Status, and Mortality in Renal Transplant Recipients. J Clin Med 2019;8:E1948. [PMID: 31726722 DOI: 10.3390/jcm8111948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
58 Davis S, Wiebe C, Campbell K, Anobile C, Aubrey M, Stites E, Grafals M, Pomfret E, Nickerson P, Cooper JE. Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort. Am J Transplant 2021;21:322-8. [PMID: 32888256 DOI: 10.1111/ajt.16290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
59 Kostalova B, Ribaut J, Dobbels F, Gerull S, Mala-Ladova K, Zullig LL, De Geest S. Medication adherence interventions in transplantation lack information on how to implement findings from randomized controlled trials in real-world settings: A systematic review. Transplant Rev (Orlando) 2021;36:100671. [PMID: 34773910 DOI: 10.1016/j.trre.2021.100671] [Reference Citation Analysis]
60 Hsiao CY, Ho MC, Ho CM, Wu YM, Lee PH, Hu RH. Long-Term Tacrolimus Blood Trough Level and Patient Survival in Adult Liver Transplantation. J Pers Med 2021;11:90. [PMID: 33535628 DOI: 10.3390/jpm11020090] [Reference Citation Analysis]
61 Helanterä I, Snyder J, Åsberg A, Cruzado JM, Bell S, Legendre C, Tedesco-silva H, Barcelos GT, Geissbühler Y, Prieto L, Christian JB, Scalfaro E, Dreyer NA. Demonstrating Benefit-Risk Profiles of Novel Therapeutic Strategies in Kidney Transplantation: Opportunities and Challenges of Real-World Evidence. Transpl Int 2022;35:10329. [DOI: 10.3389/ti.2022.10329] [Reference Citation Analysis]
62 Denhaerynck K, Berben L, Dobbels F, Russell CL, Crespo-Leiro MG, Poncelet AJ, De Geest S; BRIGHT study team. Multilevel factors are associated with immunosuppressant nonadherence in heart transplant recipients: The international BRIGHT study. Am J Transplant 2018;18:1447-60. [PMID: 29205855 DOI: 10.1111/ajt.14611] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
63 Wang Y, Veltkamp DMJ, van der Boog PJM, Hemmelder MH, Dekker FW, de Vries APJ, Meuleman Y. Illness Perceptions and Medication Nonadherence to Immunosuppressants After Successful Kidney Transplantation: A Cross-Sectional Study. Transpl Int 2022;36:10073. [DOI: 10.3389/ti.2022.10073] [Reference Citation Analysis]
64 Berger FA, Mulder MB, Ten Bosch-Dijksman W, van Schaik RHN, Coenen S, de Winter BCM. Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose. Br J Clin Pharmacol 2019;85:1852-4. [PMID: 31190414 DOI: 10.1111/bcp.13958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Vankova B, Mala-Ladova K, Kubena AA, Maly J, Sulkova SD. Immunosuppressive therapy related adherence, beliefs and self-management in kidney transplant outpatients. Patient Prefer Adherence 2018;12:2605-13. [PMID: 30584284 DOI: 10.2147/PPA.S184166] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]